Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
What's Your Reaction?
